New hope for Tough-to-Treat lung cancer: trial targets specific genetic flaw
NCT ID NCT07249372
First seen Jan 09, 2026 · Last updated Apr 20, 2026 · Updated 13 times
Summary
This study is testing an experimental drug called DRP-104 for people with advanced non-small cell lung cancer that has specific genetic changes (NFE2L2 or KEAP1) and has stopped responding to standard chemotherapy and immunotherapy. The main goal is to see if the drug can shrink tumors and control the cancer's growth. It is for adults whose cancer has progressed after prior treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University
RECRUITINGNew York, New York, 10032, United States
Contact
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.